The Philadelphia Inquirer
WASHINGTON - Medicare officials said Wednesday that the program would pay the $93,000 cost of the prostate cancer drug Provenge, an innovative therapy that typically gives men suffering from an incurable stage of the disease an extra four months to live.
The Centers for Medicare and Medicaid said the biotech drug made by
Dendreon Corp. was a "reasonable and necessary" medicine. The decision
ensures that millions of men would be able to afford the drug through
the government-backed health-care coverage. With government
reimbursement, analysts estimate Provenge could total $1 billion in
sales next year... Read More